SCHEMBL3399671

SCHEMBL3399671

Cc1nc(-c2ccc(Cl)cc2Cl)sc1C(=O)NCCN(C(C)C)C(C)C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.47
KDM4E B2RXH2 1/20 0.47
GAA P10253 2/20 0.45
SMN1; SMN2 Q16637 3/20 0.44
SHMT1 P34896 3/20 0.43
SHMT2 P34897 3/20 0.43
ALDH1A1 P00352 2/20 0.42
POLB P06746 1/20 0.42
ALPL P05186 1/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 1/20 0.41
CHRM4 P08173 1/20 0.41
DPP4 P27487 1/20 0.40
DPP8 Q6V1X1 1/20 0.40
HPGD P15428 1/20 0.40
CDC7 O00311 1/20 0.39
DBF4 Q9UBU7 1/20 0.39
SCN3A Q9NY46 1/20 0.39
PPARD Q03181 1/20 0.39
PPARA Q07869 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3400291 0.92 GAA (0.45) MAPTKDM4EGAASMN1; SMN2ALDH1A1
SCHEMBL3403688 0.88 SMN1; SMN2 (0.54) MAPTGAASMN1; SMN2ALDH1A1NPC1
SCHEMBL3405341 0.87 KDM4E (0.51) MAPTKDM4EGAASMN1; SMN2SHMT1
SCHEMBL3402994 0.85 GAA (0.63) MAPTKDM4EGAASMN1; SMN2ALDH1A1
SCHEMBL3400114 0.84 PANK3 (0.50) MAPTGAASMN1; SMN2ALDH1A1NPC1
SCHEMBL3402647 0.82 NPC1 (0.40) MAPTGAASMN1; SMN2ALDH1A1NPC1
SCHEMBL3437699 0.80 GAA (0.68) MAPTKDM4EGAASMN1; SMN2SHMT1
SCHEMBL3400054 0.79 HPGD (0.46) MAPTKDM4EGAASMN1; SMN2ALDH1A1
SCHEMBL3401355 0.79 DPP4 (0.54) MAPTKDM4EGAASMN1; SMN2ALDH1A1
SCHEMBL3398938 0.78 GAA (0.46) MAPTKDM4EGAASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100297035-A1 Thiazole Amides, Imidazole Amides and Related Analogues LIGAND PHARMACEUTICALS, INC. (US) 2010-11-25 US disclosed
US-7728009-B1 Thiazole amides, imidazole amides and related analogues NEUROGEN CORPORATION (US) 2010-06-01 US disclosed
US-7728009-B1 Thiazole amides, imidazole amides and related analogues NEUROGEN CORPORATION (US) 2010-06-01 US disclosed
US-7728009-B1 Thiazole amides, imidazole amides and related analogues NEUROGEN CORPORATION (US) 2010-06-01 US disclosed
WO-2006089076-A9 THIAZOLE AMIDES, IMIDAZOLE AMIDES AND RELATED ANALOGUES NEUROGEN CORP (US) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100297035-A1 Thiazole Amides, Imidazole Amides and Related Analogues HRH3, HRH4, HRH2 MAPT 342/4885KDM4E 3449/4885GAA 1659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.